Resource Type

Journal Article 115

Conference Videos 1

Year

2024 1

2023 12

2022 13

2021 12

2020 8

2019 11

2018 6

2017 3

2016 6

2015 1

2014 2

2013 4

2012 7

2011 1

2010 5

2009 11

2008 2

2007 5

1999 2

open ︾

Keywords

immunotherapy 6

tumor 4

metastasis 3

Chimeric antigen receptor 2

Colorectal cancer 2

Efficacy 2

Exosomes 2

PD-L1 2

Tumor 2

angiogenesis 2

cancer immunotherapy 2

cancer therapy 2

chimeric antigen receptor T cell 2

hepatocellular carcinoma 2

immune checkpoint inhibitor 2

tumor immunotherapy 2

tumor microenvironment 2

3D printing 1

4-1BB ligand 1

open ︾

Search scope:

排序： Display mode:

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellSingle-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected fromM2-subtype macrophages were significantly involved in both in vivo and in vitro anti-tumorImmunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment     tumor-associated macrophage     metabolism    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyThe simultaneous expression of target antigens by healthy organs and tumor cells is partly responsibleAlongside targeting tumor-specific antigens, targeting the aberrantly glycosylated glycoforms of tumor-associatedantigens can also minimize the off-tumor effects of CAR-T therapies.

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation    

HTML PDF Collect

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TEpidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in variousThus, EGFRvIII is a potential antigen for targeted lung cancer therapy.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Tumor-Specific CircRNA-Derived Antigen Peptide Identification for Hepatobiliary Tumors Article

Wenwen Wang, Lili Ma, Zheng Xing, Tinggan Yuan, Jinxia Bao, Yanjing Zhu, Xiaofang Zhao, Yan Zhao, Yali Zong, Yani Zhang, Siyun Shen, Xinyao Qiu, Shuai Yang, Hongyang Wang, Dong Gao, Peng Wang, Lei Chen

Engineering 2023, Volume 22, Issue 3,   Pages 159-170 doi: 10.1016/j.eng.2022.06.008

Abstract:

The application of tumor antigen-based immunotherapy is hindered by the rarity of validated immunogenicantigen peptides in hepatobiliary tumor organoids.were predicted to generate 18 971 antigen peptides in 27 organoids.In view of the antigen landscape, 11 amino acid length (mer) peptides and human leukocyte antigen (HLAtumor-specific circRNAs in cancers.

Keywords： Tumor antigen     Patient-derived hepatobiliary tumor organoid     Circular RNA     Mass-spectrometry-based immunopeptidomics    

HTML PDF Collect

Heterogeneity of the tumor immune microenvironment and clinical interventions

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 617-648 doi: 10.1007/s11684-023-1015-9

Abstract: Heterogeneity of the tumor immune microenvironment and clinical interventions

Keywords： Heterogeneity tumor immune    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-celltumors, prompting scientists and doctors to exploit this strategy to treat other tumor types.Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Frontiers of Medicine 2013, Volume 7, Issue 3,   Pages 306-315 doi: 10.1007/s11684-013-0279-x

Abstract: transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen

Keywords： partially matched related donor     hematopoietic stem cell transplantation     allogeneic    

HTML PDF Collect

Proteins moonlighting in tumor metabolism and epigenetics

Lei Lv, Qunying Lei

Frontiers of Medicine 2021, Volume 15, Issue 3,   Pages 383-403 doi: 10.1007/s11684-020-0818-1

Abstract: interplay of multiple signaling pathways and restrained by oxygen and nutrient accessibility in the tumorThe signal−moonlighting protein−metabolism axis facilitates the adaptation of tumor cells under varying

Keywords： moonlighting function     tumor metabolism     epigenetics    

HTML PDF Collect

Complex interplay between tumor microenvironment and cancer therapy

Minhong Shen, Yibin Kang

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 426-439 doi: 10.1007/s11684-018-0663-7

Abstract:

Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist withinand around the tumor mass.Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME

Keywords： tumor microenvironment     therapy response     treatment resistance    

HTML PDF Collect

Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives

Bingxue Shang, Zhifei Cao, Quansheng Zhou

Frontiers of Medicine 2012, Volume 6, Issue 1,   Pages 67-78 doi: 10.1007/s11684-012-0176-8

Abstract: Although the current antiangiogenic drugs reduce the density of tumor blood vessels and result in tumor, which fosters tumor cells to become more aggressive and metastatic.on the pioneering work on tumor blood vessels by several other researchers.roles in tumor neovascularization, growth, and metastasis.Therefore, multiple-targeting of vasculogenic tumor cells and genes may improve the efficacy of tumor

Keywords： angiogenesis     vasculogenesis     neovascularization     tumor     vasculature     normalization     traditional Chinese medicine    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 457-462 doi: 10.1007/s11684-010-0240-1

Abstract: This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen

Keywords： cholangiocarcinoma     prognostic factors     serum carbohydrate antigen 19-9    

HTML PDF Collect

Natural killer cell lines in tumor immunotherapy

Min Cheng, Jian Zhang, Wen Jiang, Yongyan Chen, Zhigang Tian

Frontiers of Medicine 2012, Volume 6, Issue 1,   Pages 56-66 doi: 10.1007/s11684-012-0177-7

Abstract: genetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumorantigen receptors could improve their specificity and cytotoxicity.In this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines

Keywords： natural killer cell     natural killer cell line     tumor immunotherapy     genetic modification    

HTML PDF Collect

Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

Kai Shi, Matthew Haynes, Leaf Huang

Frontiers of Chemical Science and Engineering 2017, Volume 11, Issue 4,   Pages 676-684 doi: 10.1007/s11705-017-1640-4

Abstract: Specifically, reversing the immune-suppressive effects of the tumor microenvironment, mediated by a variety

Keywords： vaccine     nanoparticle     tumor     immunotherapy     microenvironment    

HTML PDF Collect

Title Author Date Type Operation

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Tumor-Specific CircRNA-Derived Antigen Peptide Identification for Hepatobiliary Tumors

Wenwen Wang, Lili Ma, Zheng Xing, Tinggan Yuan, Jinxia Bao, Yanjing Zhu, Xiaofang Zhao, Yan Zhao, Yali Zong, Yani Zhang, Siyun Shen, Xinyao Qiu, Shuai Yang, Hongyang Wang, Dong Gao, Peng Wang, Lei Chen

Journal Article

Heterogeneity of the tumor immune microenvironment and clinical interventions

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Journal Article

Proteins moonlighting in tumor metabolism and epigenetics

Lei Lv, Qunying Lei

Journal Article

Complex interplay between tumor microenvironment and cancer therapy

Minhong Shen, Yibin Kang

Journal Article

Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives

Bingxue Shang, Zhifei Cao, Quansheng Zhou

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Journal Article

Natural killer cell lines in tumor immunotherapy

Min Cheng, Jian Zhang, Wen Jiang, Yongyan Chen, Zhigang Tian

Journal Article

Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

Kai Shi, Matthew Haynes, Leaf Huang

Journal Article